Source:http://linkedlifedata.com/resource/pubmed/id/20874646
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2010-9-29
|
pubmed:abstractText |
In the early 1990s, Linsley and colleagues produced a soluble fusion protein, comprising of the extracellular domain of cytotoxic T lymphocyte antigen (CTLA)4 and the human IgG1 Fc domain. Since then, several hundreds of scientific publications have demonstrated that CTLA4-Ig blocks CD28-mediated co-stimulation and suppresses unwanted T cell-mediated responses in animal models of transplantation, autoimmunity and inflammation. In the past two decades, Bristol-Myers Squibb Co. has developed abatacept, a CTLA4-Ig molecule for treating psoriasis and rheumatoid arthritis, and belatacept, a second-generation, higher affinity CTLA4-Ig molecule for use in kidney transplantation. Belatacept represents a new class of transplantation immunosuppressants and potentially offers clinicians a breakthrough therapy to preserve kidney function in the long term and reduce the side effects of current immunosuppressive therapies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1750-7448
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
2
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
625-36
|
pubmed:meshHeading |
pubmed-meshheading:20874646-Animals,
pubmed-meshheading:20874646-Antirheumatic Agents,
pubmed-meshheading:20874646-Calcineurin,
pubmed-meshheading:20874646-Clinical Trials as Topic,
pubmed-meshheading:20874646-Disease Models, Animal,
pubmed-meshheading:20874646-Drug Approval,
pubmed-meshheading:20874646-Drug Discovery,
pubmed-meshheading:20874646-Graft Rejection,
pubmed-meshheading:20874646-Humans,
pubmed-meshheading:20874646-Immunoconjugates,
pubmed-meshheading:20874646-Immunosuppression,
pubmed-meshheading:20874646-Kidney Transplantation,
pubmed-meshheading:20874646-Lymphocyte Activation,
pubmed-meshheading:20874646-Signal Transduction
|
pubmed:year |
2010
|
pubmed:articleTitle |
Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker.
|
pubmed:affiliation |
INSERM, UMR643, Nantes F44093, France.
|
pubmed:publicationType |
Journal Article,
Review
|